Breaking News

CPHI Frankfurt Report Predicts Biologics Outsourcing Surge in 2023

Access to trained staff is the major challenge ahead, with single use systems and automation only moderately reducing demand.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ahead of the world’s largest pharma event, CPHI Frankfurt—hosted at the Frankfurt Messe (1-3 November, 2022) – part i of the CPHI Annual Report looks ahead at the opportunities for biologics production and CMOs in 2023. Having already benefitted from a Covid-based boom in the last two years, outsourcing of biologics globally is set to continue growing significantly in 2023—with no production cliff expected as Covid contracts reduce in scale. The report’s authors identified that nearly 36% of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters